Canopy Growth Revenue Rises 22% As International Cannabis Sales Jump 141%, But Net Loss Widens To C$40.7 Million

A C$35.8 million fair value charge on Canopy USA assets swamped a quarter of growth, and the CFO says positive adjusted EBITDA is within reach.

Share
Canopy Growth Revenue Rises 22% As International Cannabis Sales Jump 141%, But Net Loss Widens To C$40.7 Million

Canopy Growth, which grows and sells cannabis mainly in Canada, reported net revenue of C$81.4 million for its fiscal second quarter, up 22% from a year earlier. Its net loss still widened to C$40.7 million from C$5.0 million, which the company blamed on C$35.8 million of fair value charges on assets tied to Canopy USA.

Europe leads a broad revenue gain

The Cannabis segment grew 30% to C$66.2 million. International cannabis sales rose 141% to C$12.3 million from C$5.1 million, which the company attributed mainly to medical cannabis sales in Germany and Poland.

Canada medical cannabis revenue climbed 18% to C$25.8 million, helped by more insured customers and the MTL Cannabis acquisition, and partly offset by a cut in the Veterans Affairs Canada reimbursement rate. Canada adult-use revenue rose 17% to C$28.1 million, mainly on flower sales from MTL Cannabis, partly offset by lower opportunistic bulk sales.

Storz & Bickel, the company's vaporizer business, fell 4% to C$15.1 million as customers in some regions spent less.

Margins slip and the loss balloons

Consolidated gross margin was 29%, against 33% a year earlier. Adjusted gross margin was 31%; the company excluded C$2.1 million of inventory step-up charges from the MTL deal. Cannabis gross margin fell to 26% from 31%. Selling, general and administrative costs rose 9%, driven by MTL's operations and partly offset by headcount cuts.

The net loss rose by C$35.7 million, which the company tied to C$35.8 million of fair value charges on Canopy USA related assets. Canopy Growth holds a non-controlling, non-voting interest in Canopy USA, an entity that participates in US cannabis sales.

The path to positive adjusted EBITDA

Adjusted EBITDA, a profit measure that strips out items such as depreciation and stock pay, was a loss of C$2.9 million, C$0.2 million better than a year earlier. Free cash outflow narrowed to C$15.5 million from C$19.2 million.

CFO Tom Stewart said the company is "progressing steadily to profitability" and within reach of positive adjusted EBITDA during fiscal 2027. CEO Luc Mongeau pointed to a U.K. market entry, a new German country manager and EU GMP certification of the Smiths Falls facility.

Cash and equivalents stood at C$247.3 million at September 30, down from C$364.7 million at March 31.

Management discusses the results on a call at 10:00 a.m. ET Friday, with a replay available until February 4, 2027.

Sources

More on Canopy Growth

All Canopy Growth (CGC) coverage →